Ovarian cancer biology and immunotherapy
/in Dendritic Cells, International Publications, Ovarian CancerAutologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC).
/in Dendritic Cells, International Publications, Ovarian CancerThe feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
/in Dendritic Cells, International Publications, Ovarian CancerWilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer, Uterine CancerDendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian CancerDendritic cell-based immunotherapy in ovarian cancer
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian CancerImmunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian CancerA dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside
/in Dendritic Cells, International Publications, Ovarian CancerA Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer